Photo: Science Photo Library / Science Photo Library / Getty Images
Now, Japanese researchers are moving a promising, tooth-regrowing medicine into human trials—the first patients will be receiving the drug intravenously in September of this year.
If the trial is successful, the researchers hope the drug will become available for all forms of toothlessness sometime around 2030
“We want to do something to help those who are suffering from tooth loss or absence,” Katsu Takahashi, the head of dentistry at the medical research institute at Kitano Hospital in Osaka, told The Mainichi. “While there has been no treatment to date providing a permanent cure, we feel that people’s expectations for tooth growth are high.”
This development follows years of study around a particularly antibody named Uterine sensitization–associated gene-1 (USAG-1), which has been shown to inhibit the growth of teeth in ferrets and mice. Back in 2021, scientists from the Kyoto University—who will also be involved in future human trials—discovered a monoclonal antibody (a technique usually used in fighting cancer) that disrupted the interaction between USAG-1 and molecules known as bone morphogenetic protein, or BMP.
Click Here To Listen Live https://www.iheart.com/live/news-radio-wtam-1100-17